Wyeth

Pfizer Corporation

Wyeth Holdings Corporation

Justin Keith Moran

Mark Edward Ruppen

Annaliesa Sybil Anderson

Kathrin Ute Jansen

Robert G K Donald

Maninder K Sidhu

Michael James Flint

Narender Kumar Kalyan

Susan Kay Hoiseth

John W Simpson

Jason Arnold Lotvin

Nishith Merchant

Jianxin Gu

Ling Chu

Eugene Joseph Vidunas

Andrew George Popplewell

Nitin Krishnaji Damle

Arthur Kunz

Joseph Thomas Rubino

John Francis DiJoseph

Weiqiang Sun

Neera Jain

Paul David Robbins

Wei-Qiang Willie Sun

Yonghui Yuan

James Patch

Avvari Krishna Prasad

Jin-Hwan Kim

Wei Chen

Srinivas Kodali

Laurent Oliver Chorro

Suddham Singh

Rosalind Pan

Scott Ellis Lomberk

Karen Kiyoko Takane

Pamela S Fink

Gary Warren Zlotnick

John Erwin Farley

Liesel A Bernfield

Pamela Fink Charbonneau

Deborah Ann Dilts

John McLean Simpson

Robert G Donald

Terri L Mininni

Scott Andrew Cook

Robert GK Donald

Arthur Kuntz

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

compositions and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturingand in producingtoxins.

Compositions and methods relating to a mutanttoxin

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to a non-lipidated and non-pyruvylatedserogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

composition and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutanttoxin and methods thereof

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B, and methods related thereto.

Non-lipidated variants ofORF2086 antigens

Compositions and methods relating to a mutant clostridium difficile toxin

Growing community of inventors

Valley Cottage, NY, United States of America

Justin Keith Moran